NCT03367403: A Study of LY3002813 in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ)
- State
- Completed
- Phase
- Phase 2
- People
- 272 taking part
- Started
- 18 Dec 2017
- Primary completion
- 4 Dec 2020
- Arms
- Donanemab Monotherapy (Donanemab-M)
- Results
- Posted on the registry
- 8 Dec 2017: Trial registered
- 18 Dec 2017: Trial started
- 21 Sep 2021: Trial completed
- 15 Feb 2022: Trial results posted